AIM ImmunoTech Announces Print Publication Of Data Analysis From Early Access Program Studying Ampligen
Author: Benzinga Newsdesk | August 20, 2024 08:32am
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM") today announced the official print publication of the data analysis from a long-term Early Access Program ("EAP") studying the company's drug Ampligen® (rintatolimod) for the treatment of advanced pancreatic ductal adenocarcinoma ("PDAC"). The manuscript titled "Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses," appears in the journal Clinical Cancer Research, one of oncology's most prestigious journals.
Posted In: AIM